Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Elafibranor
(D11208)		1件: Elafibranor1件: Elafibranor (D11208) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬2件: 93, 94 💬
2Elafibranor 120 MG
(D11208)		1件: Elafibranor1件: Elafibranor (D11208) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬2件: 93, 94 💬
3Elafibranor 80 MG
(D11208)		1件: Elafibranor1件: Elafibranor (D11208) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬2件: 93, 94 💬
4Elafibranor 80MG
(D11208)		1件: Elafibranor1件: Elafibranor (D11208) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬